tirzepatide patent expiration 2036 As the patents on semaglutide, a popular diabetes and anti-obesity drug that earned its Danish maker Novo Nordisk nearly USD 30 billion in FY25 alone, expire in nearly 100 countries next year Semaglutide & Tirzepatide Patent Considerations

This mechanism contributes to improved glycemic control by reducing postprandial glucose excursions and promotes satiety, supporting weight loss

Compare multiple vendors systematically

If weight loss or changes in metabolism affect your thyroid function, it could also contribute to feeling cold

compounded medication, and your savings programs to qualify

Nanda N, Alphonse MP

News provided by Eli Lilly and Company May 21, 2026, 06:45 ET In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving 30% weight loss, a level long associated with bariatric surgery Individuals with a baseline BMI 35 who participated in a study extension continued to lose weight, and achieved up to an average of 85.0 lbs (30.3%) weight loss at 104 weeks At the 4 mg dose, reached with only a single escalation step, participants lost an average of 47.2 lbs (19.0%) at 80 weeks with a lower observed discontinuation rate due to adverse events vs